Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Marshall Wace LLP

Marshall Wace LLP cut its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 98.2% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,326 shares of the medical equipment provider's stock after selling 448,736 shares during the period. Marshall Wace LLP's holdings in Lantheus were worth $668,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of LNTH. Silverberg Bernstein Capital Management LLC increased its holdings in Lantheus by 0.4% in the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider's stock worth $1,834,000 after buying an additional 100 shares during the period. Moody National Bank Trust Division raised its holdings in shares of Lantheus by 1.1% during the second quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider's stock worth $1,203,000 after purchasing an additional 162 shares during the last quarter. NBC Securities Inc. lifted its position in Lantheus by 28.4% during the first quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider's stock valued at $53,000 after purchasing an additional 191 shares during the period. GAMMA Investing LLC lifted its position in Lantheus by 184.1% during the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock valued at $26,000 after purchasing an additional 208 shares during the period. Finally, Retirement Systems of Alabama boosted its holdings in Lantheus by 0.3% in the first quarter. Retirement Systems of Alabama now owns 86,005 shares of the medical equipment provider's stock valued at $5,353,000 after purchasing an additional 226 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on LNTH shares. Redburn Atlantic initiated coverage on Lantheus in a research report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price target for the company. B. Riley boosted their target price on shares of Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a research note on Thursday, July 25th. JMP Securities dropped their price target on shares of Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 1st. Leerink Partners lifted their price objective on shares of Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a report on Thursday, July 11th. Finally, Truist Financial lowered their target price on shares of Lantheus from $141.00 to $135.00 and set a "buy" rating on the stock in a research note on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $126.00.

Insider Buying and Selling at Lantheus

In other news, CAO Andrea Sabens sold 341 shares of the business's stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $123.15, for a total transaction of $41,994.15. Following the transaction, the chief accounting officer now owns 62,216 shares of the company's stock, valued at approximately $7,661,900.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Lantheus news, Director Mary Anne Heino sold 10,481 shares of the firm's stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $95.50, for a total transaction of $1,000,935.50. Following the completion of the sale, the director now owns 454,923 shares of the company's stock, valued at $43,445,146.50. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Andrea Sabens sold 341 shares of the company's stock in a transaction on Monday, July 15th. The shares were sold at an average price of $123.15, for a total value of $41,994.15. Following the completion of the transaction, the chief accounting officer now directly owns 62,216 shares in the company, valued at approximately $7,661,900.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 28,322 shares of company stock worth $2,731,150 in the last three months. 1.50% of the stock is owned by corporate insiders.

Lantheus Price Performance

Shares of NASDAQ LNTH traded up $1.17 during mid-day trading on Wednesday, reaching $109.27. The company's stock had a trading volume of 309,913 shares, compared to its average volume of 988,513. The stock has a market capitalization of $7.57 billion, a P/E ratio of 16.50 and a beta of 0.50. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $126.89. The stock has a 50-day moving average of $103.63 and a two-hundred day moving average of $88.44. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing analysts' consensus estimates of $1.68 by ($0.07). The business had revenue of $394.10 million during the quarter, compared to analysts' expectations of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The company's revenue for the quarter was up 22.5% compared to the same quarter last year. During the same period last year, the business earned $1.40 earnings per share. On average, equities research analysts anticipate that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.